HiFiBiO SAS to present advances in functional therapeutic antibody discovery at PEPTalk, January 12, 2017

CAMBRIDGE, Mass. & PARIS--()--HiFiBiO SAS today announced that the latest results from their CelliGOTM platform will be presented by Dr. Roshan Kumar, Group Leader in Cambridge, as part of the 'Emerging Technologies for Antibody Discovery' track at PEPTalk 2017 in San Diego. The presentations will feature the latest achievements in deep mining human and rodent immune repertoires for therapeutic antibody discovery and deep mining approaches to addressing challenging targets such as cell surface targets using in-droplet functional assays.

Presentation Title: Functional Therapeutic Antibody Discovery for Challenging Targets by Single-B-cell Screening in Nano-droplets. The presentation will be on Thursday, Jan. 12 at 3:05 PST.

About HiFiBiO

HiFiBiO’s platform employs paired molecular barcoding, next-generation sequencing, and rapid DNA synthesis coupled to high-throughput antibody cloning and expression enabling single-cell-based screening of entire antibody-secreting B cell populations. Identification of diverse high quality leads is expected to lower the risk of developing optimized antibody drug candidates. The company has entered into multiple antibody discovery collaborations with leading pharmaceutical companies. Learn more at www.hifibio.com.


Colin J.H. Brenan, Ph.D., +1-781-248-9318
Chief Commercial Officer

Release Summary

HiFiBiO to present advances in single B-cell in-droplet functional screening capabilities at PEPTalk this week in San Diego as part of Emerging Technologies in Antibody Discovery track.